Case Report
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Radiol. Oct 28, 2024; 16(10): 579-585
Published online Oct 28, 2024. doi: 10.4329/wjr.v16.i10.579
Successful management of infection and macrophage activation syndrome patient using low-dose etoposide: A case report
Shu-Pei Gao, Xiao-Fang Luo, Mohammadreza Kosari, Wen-Juan Li, Liu Yang, Wei Tu, Ji-Xin Zhong
Shu-Pei Gao, Xiao-Fang Luo, Mohammadreza Kosari, Wen-Juan Li, Department of Rheumatology, Tongji Hospital, Wuhan 430030, Hubei Province, China
Liu Yang, Reproductive Medicine Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, Hubei Province, China
Wei Tu, Department of Rheumatology and Immunology, Tongji Hospital, Huazhong University of Science and Technology, Wuhan 430030, Hubei Province, China
Ji-Xin Zhong, Department of Rheumatology and Immunology, Tongji Hospital of Tongji Medical College, Wuhan 430030, Hubei Province, China
Co-corresponding authors: Wei Tu and Liu Yang.
Author contributions: Gao SP, Luo XF and Kosari M contributed equally to this study (responsible for data collection and analysis); Zhong JX, Tu W, and Yang L contribute equally to the study design and data analysis; Gao SP, Li WJ, and Kosari M drew the data and drafted the manuscript; Zhong JX revised the manuscript. All authors have confirmed the final approval.
Supported by Hubei Provincial Natural Science Foundation of China, No. 2023AFB771; and National Natural Science Foundation of China, No. 82270903 and No. 81974254.
Informed consent statement: The patient provided a verbal informed consent for the documentation of her case.
Conflict-of-interest statement: The authors declare no conflict of interest.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Wei Tu, Department of Rheumatology and Immunology, Tongji Hospital, Huazhong University of Science and Technology, No. 1095 Jiefang Ave., Wuhan 430030, Hubei Province, China. zhongjixin620@163.com
Received: May 16, 2024
Revised: September 5, 2024
Accepted: September 24, 2024
Published online: October 28, 2024
Processing time: 165 Days and 4.1 Hours
Core Tip

Core Tip: Etoposide has been utilized in severe and refractory cases of macrophage activation syndrome (MAS). However, in cases where severe infections and autoimmune disorders are present concurrently, the use of etoposide carries the risk of bone marrow suppression and exacerbation of infections. In this case report, we successfully avoided bone marrow suppression and controlled both MAS and severe infection in patients in such condition by using a modified etoposide regimen.